Registered title, quoted from ClinicalTrials.gov
Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Huashan Hospital; 2 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 3
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorHuashan Hospital复旦大学附属华山医院ShanghaiHospital page
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06679244, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
The primary lesion was diagnosed as adenocarcinoma through endoscopic biopsy and histopathological examination;
Inclusion criterion 3
Preoperative ECOG (Eastern Cooperative Oncology Group) physical status score 0/1;
Inclusion criterion 8
Suffering from other malignant tumors within 5 years;
Exclusion criterion 3
Pregnant and lactating women;
Exclusion criterion 2
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06679244, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 18 years old ≤ 80 years old;
- The primary tumor lesion is located in the upper part of the stomach or the esophagogastric junction (Siewert II or III), and it is expected that R0 surgical results can be obtained by performing proximal gastrectomy and D2 dissection;
- The primary lesion was diagnosed as adenocarcinoma through endoscopic biopsy and histopathological examination;
- If it is upper gastric adenocarcinoma, the clinical TNM staging based on imaging needs to be cT1N0M0. If it is ductal gastric junction adenocarcinoma, it needs to be cT1-3N0-1M0, and clinical imaging judgment shows no distant gastric lymph node metastasis;
- Expected survival exceeds 6 months;
- No history of upper abdominal surgery (excluding laparoscopic cholecystectomy);
- No chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc. were performed before surgery;
- Preoperative ECOG (Eastern Cooperative Oncology Group) physical status score 0/1;
- Preoperative ASA (American Society of Anesthesiologists) grading I-III ;
- Good function of important organs;
- Sign the patient's informed consent form
Exclusion Criteria:
- Preoperative imaging examination suggests the fusion of enlarged lymph nodes (maximum diameter ≥ 3cm) in the area;
- Pregnant and lactating women;
- Suffering from other malignant tumors within 5 years;
- Preoperative body temperature ≥ 38 ℃ or complicated with infectious diseases requiring systematic treatment;
- Serious mental illness;
- Severe respiratory diseases, FEV1<50% of the expected value;
- Severe liver and kidney dysfunction;
- History of unstable angina or heart attack within 6 months;
- History of cerebral infarction or cerebral hemorrhage within 6 months, excluding old intracavitary infarction;
- Apply systemic corticosteroid therapy within one month;
- Patients with complications of gastric cancer (bleeding, perforation, obstruction) requiring emergency surgery;
- The patient has participated or is currently participating in other clinical studies (within 6 months)
Quoted from ClinicalTrials.gov, NCT06679244, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06679244, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.